Copyright
©The Author(s) 2017.
World J Gastrointest Endosc. Apr 16, 2017; 9(4): 153-161
Published online Apr 16, 2017. doi: 10.4253/wjge.v9.i4.153
Published online Apr 16, 2017. doi: 10.4253/wjge.v9.i4.153
ENETS | AJCC | |
T Grade (primary tumor) | ||
Tx | Primary tumor is not assessed | Primary tumor is not assessed |
T0 | No finding of primary tumor | No finding of a primary tumor |
Tis | In situ carcinoma | |
T1 | Tumor is limited to the pancreas and < 2 cm | Tumor is limited to the pancreas and ≤ 2 cm |
T2 | Tumor is limited to the pancreas and 2 to 4 cm | T2 tumor is limited to the pancreas and > 2 cm |
T3 | Tumor is limited to the pancreas and > 4 cm or with positive duodenum or biliary tract invasion | Tumor has progressed beyond the pancreas but there is no celiac or mesenteric artery involvement |
T4 | Tumor has invaded the neighboring organs (stomach, spleen, colon, adrenal gland) or walls of the large vessels (celiac artery or superior mesenteric artery) | Tumor shows celiac or superior mesenteric artery involvement |
N-lymph node status | ||
Nx | Regional lymph nodes are not assessed | Regional lymph nodes are not assessed |
N0 | No regional lymph node metastasis | No regional lymph node metastasis |
N1 | Regional lymph node metastasis is positive | Regional lymph node metastasis is positive |
M-distant metastasis | ||
Mx | Distant metastasis is not assessed | |
M0 | No distant metastasis | No distant metastasis |
M1 | Distant metastasis is positive | Distant metastasis is positive |
Stage | ||
0 | Tis, N0, M0 | |
I | T1, N0, M0 | |
IA | T1, N0, M0 | |
IB | T2, N0, M0 | |
IIA | T2, N0, M0 | T3, N0, M0; T1, N1, M0 |
IIB | T3, N0, M0 | T2, N1, M0; T3,N1,M0 |
III | T4, Any N, M0 | |
IIIA | T4, N0, M0 | |
IIIB | Any T, N1, M0 | |
IV | Any T, Any N, M1 | Any T, Any N, M1 |
Ref. | Study period | Patients (n) | Group | Number of patients n (%) | 5-yr PFS rates (%) | P value | Median follow-up time (mo) |
Cheema et al[18] | 1999-2010 | 143 | Incidental | 56 (40) | 86 | 0.07 | 67 (mean) |
Non-incidental | 87 (60) | 59 | |||||
Crippa et al[54] | 1990-2009 | 355 | Incidental | 124 (35) | 83 | < 0.001 | 44 |
Non-incidental | 231 (65) | 32 | |||||
Haynes et al[53] | 1997-2009 | 139 | Incidental | 109 (82) | 82.8 | 0.27 | 34.2 |
Non-incidental | 30 (18) | 81.7 | |||||
Birnbaum et al[55] | 1994-2010 | 108 | Incidental | 65 (61) | 92 | 0.03 | 42 |
Non-incidental | 43 (39) | 82 |
Ref. | Study period | Patients n | Group | Number of patients n (%) | Median follow-up time (mo) | Surgery morbidity rate (%) |
Gaujoux et al[56] | 2000-2011 | 46 | Observational | 38 (83) | > 18 | 62 |
Surgery | 8 (17) | 27 | ||||
Lee et al[57] | 2000-2011 | 133 | Observational | 77 (57) | 44 (Mean) | 46 |
Surgery | 56 (43) | 52 (Mean) | ||||
Rosenberg et al[58] | 1999-2014 | 35 | Observational | 15 (42) | 28 | 35 |
Surgery | 20 (58) | 34 | ||||
Sharpe et al[60] | 1998-2006 | 380 | Observational | 71 (19) | 60 | N/A |
Surgery | 309 (81) | 60 | ||||
Sadot et al[59] | 1993-2013 | 181 | Observational | 1042 (57) | 44 | N/A |
Surgery | 771 (43) | 57 |
- Citation: Bar-Moshe Y, Mazeh H, Grozinsky-Glasberg S. Non-functioning pancreatic neuroendocrine tumors: Surgery or observation? World J Gastrointest Endosc 2017; 9(4): 153-161
- URL: https://www.wjgnet.com/1948-5190/full/v9/i4/153.htm
- DOI: https://dx.doi.org/10.4253/wjge.v9.i4.153